Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Set to Join the Russell 3000® and Russell 2000® Indexes
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company is set to join the broad-market Russell 3000 ® Index and the small-cap Russell...
View HTML
Toggle Summary Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial
FDA Grants Orphan Drug Designation for DCR-PHXC for the Treatment of Primary Hyperoxaluria CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 30, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that...
View HTML
Toggle Summary Dicerna to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a...
View HTML
Toggle Summary Dicerna to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a...
View HTML
Toggle Summary Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 14, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the...
View HTML
Toggle Summary Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on...
View HTML
Toggle Summary Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam
Company’s Resources Focused on Advancement of All Key Pipeline Programs CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- Dicerna Pharmaceuticals, Inc . (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has...
View HTML
Toggle Summary Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a...
View HTML
Toggle Summary Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will provide a corporate overview at...
View HTML
Toggle Summary Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter...
View HTML